SCHEMBL5702000

SCHEMBL5702000

CCc1cc(NC(=O)C(C)(C)C)c(OC)nc1C

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PI4KB Q9UBF8 1/20 0.40
KDM4E B2RXH2 4/20 0.40
SMN1; SMN2 Q16637 6/20 0.38
HTT P42858 3/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
PIK3CD O00329 1/20 0.37
MAPT P10636 4/20 0.37
GAA P10253 4/20 0.36
LMNA P02545 3/20 0.36
HPGD P15428 2/20 0.36
ALDH1A1 P00352 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ALOX15 P16050 1/20 0.35
ALOX12 P18054 1/20 0.35
CFTR P13569 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9058235 0.84 MAPT (0.38) SMN1; SMN2RAB9AMAPTGAAALDH1A1
SCHEMBL8699764 0.82 KDM4E (0.46) KDM4ESMN1; SMN2HTTNPC1RAB9A
SCHEMBL9058236 0.81 SMN1; SMN2 (0.35) SMN1; SMN2MAPTGAALMNAALDH1A1
SCHEMBL8594445 0.80 GRM1 (0.37) KDM4ESMN1; SMN2MAPTGAAHPGD
SCHEMBL6953240 0.77 KMT2A (0.46) KDM4ESMN1; SMN2HTTNPC1RAB9A
SCHEMBL8699464 0.76 MAPT (0.37) KDM4ESMN1; SMN2NPC1RAB9AMAPT
SCHEMBL8699278 0.75 KMT2A (0.42) KDM4ESMN1; SMN2HTTMAPTGAA
SCHEMBL7626369 0.73 MAPT (0.45) KDM4ESMN1; SMN2HTTRAB9AMAPT
SCHEMBL9266046 0.73 GAA (0.52) KDM4ESMN1; SMN2NPC1RAB9AMAPT
SCHEMBL8699897 0.72 GAA (0.41) KDM4ESMN1; SMN2HTTRAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1073637-B1 3-(AMINO- OR AMINOALKYL)PYRIDINONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF HIV RELATED DISEASES CENTRE NAT RECH SCIENT (FR) 2006-08-02 EP disclosed
US-6683079-B2 REVERSE TRANSCRIPTASE INHIBITORS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2004-01-27 US disclosed
US-20030125340-A1 Reverse transcriptase inhibitors CENTRE NATIONAL DE LA RECHERCHE SCIENT. (FR) 2003-07-03 US disclosed
US-6451822-B1 3-(Amino- or aminoalkyl)pyridinone derivatives and their use for the treatment of HIV related diseases CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2002-09-17 US disclosed
EP-1073637-A1 3-(AMINO- OR AMINOALKYL)PYRIDINONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF HIV RELATED DISEASES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2001-02-07 EP disclosed
WO-1999055676-A1 3-(AMINO- OR AMINOALKYL)PYRIDINONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF HIV RELATED DISEASES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 1999-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125340-A1 Reverse transcriptase inhibitors QTRT1, RTF2, POLR1A PI4KB 1720/4885KDM4E 534/4885SMN1; SMN2 3825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.